Amarin Co. plc (NASDAQ:AMRN) Stock Holdings Lessened by Eversept Partners LP

Share on StockTwits

Eversept Partners LP decreased its stake in shares of Amarin Co. plc (NASDAQ:AMRN) by 24.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,558,065 shares of the biopharmaceutical company’s stock after selling 502,222 shares during the period. Amarin makes up 8.6% of Eversept Partners LP’s investment portfolio, making the stock its 2nd largest holding. Eversept Partners LP owned approximately 0.44% of Amarin worth $30,211,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Mcclain Value Management LLC boosted its stake in shares of Amarin by 2.5% during the 2nd quarter. Mcclain Value Management LLC now owns 23,431 shares of the biopharmaceutical company’s stock valued at $454,000 after purchasing an additional 577 shares in the last quarter. Global Retirement Partners LLC boosted its stake in Amarin by 30.7% during the first quarter. Global Retirement Partners LLC now owns 3,414 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 802 shares in the last quarter. West Chester Capital Advisors Inc. boosted its stake in Amarin by 1.4% during the second quarter. West Chester Capital Advisors Inc. now owns 60,607 shares of the biopharmaceutical company’s stock worth $1,175,000 after acquiring an additional 815 shares in the last quarter. US Bancorp DE boosted its stake in Amarin by 16.0% during the second quarter. US Bancorp DE now owns 6,229 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 858 shares in the last quarter. Finally, Glen Harbor Capital Management LLC boosted its stake in Amarin by 4.0% during the second quarter. Glen Harbor Capital Management LLC now owns 22,616 shares of the biopharmaceutical company’s stock worth $439,000 after acquiring an additional 880 shares in the last quarter. 47.94% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ AMRN traded up $0.08 during midday trading on Friday, hitting $16.83. The stock had a trading volume of 69,637 shares, compared to its average volume of 6,576,359. The business’s 50 day moving average is $16.08 and its 200-day moving average is $18.42. The company has a market cap of $5.83 billion, a P/E ratio of -42.87 and a beta of 1.27. Amarin Co. plc has a 52 week low of $2.65 and a 52 week high of $23.91. The company has a quick ratio of 1.76, a current ratio of 2.01 and a debt-to-equity ratio of 0.18.

Amarin (NASDAQ:AMRN) last issued its earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.01. The firm had revenue of $100.40 million for the quarter, compared to the consensus estimate of $99.54 million. Amarin had a negative net margin of 27.51% and a negative return on equity of 111.75%. The business’s revenue was up 90.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.10) earnings per share. As a group, analysts expect that Amarin Co. plc will post -0.2 EPS for the current fiscal year.

In other news, Director Lars Ekman sold 91,016 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $15.01, for a total transaction of $1,366,150.16. Following the completion of the transaction, the director now directly owns 13,500 shares of the company’s stock, valued at $202,635. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Aaron Berg sold 113,195 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $18.59, for a total transaction of $2,104,295.05. The disclosure for this sale can be found here. In the last quarter, insiders sold 659,202 shares of company stock worth $13,058,754. Insiders own 2.75% of the company’s stock.

Several equities research analysts recently commented on AMRN shares. Roth Capital set a $31.00 price objective on shares of Amarin and gave the stock a “buy” rating in a research note on Friday, September 6th. Cantor Fitzgerald set a $35.00 price objective on shares of Amarin and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Stifel Nicolaus reissued a “buy” rating and set a $26.00 price objective on shares of Amarin in a research note on Wednesday, July 31st. Leerink Swann set a $26.00 price objective on shares of Amarin and gave the stock a “buy” rating in a research note on Tuesday. Finally, Svb Leerink started coverage on shares of Amarin in a research note on Wednesday, August 14th. They set an “outperform” rating and a $26.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Amarin presently has a consensus rating of “Buy” and a consensus target price of $29.50.

Amarin Company Profile

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.

Featured Story: What is included in the gross domestic product?

Want to see what other hedge funds are holding AMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amarin Co. plc (NASDAQ:AMRN).

Institutional Ownership by Quarter for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Eversept Partners LP Has $15.71 Million Stake in Ascendis Pharma A/S
Eversept Partners LP Has $15.71 Million Stake in Ascendis Pharma A/S
Amarin Co. plc  Stock Holdings Lessened by Eversept Partners LP
Amarin Co. plc Stock Holdings Lessened by Eversept Partners LP
Eversept Partners LP Cuts Stock Holdings in Sanofi SA
Eversept Partners LP Cuts Stock Holdings in Sanofi SA
Eversept Partners LP Makes New $6.32 Million Investment in Alnylam Pharmaceuticals, Inc.
Eversept Partners LP Makes New $6.32 Million Investment in Alnylam Pharmaceuticals, Inc.
Eversept Partners LP Buys 8,930 Shares of argenx SE –
Eversept Partners LP Buys 8,930 Shares of argenx SE –
Eversept Partners LP Has $20.76 Million Holdings in Danaher Co.
Eversept Partners LP Has $20.76 Million Holdings in Danaher Co.


© 2006-2019 Ticker Report